U.S. FDA authorizes AstraZeneca's COVID-19 antibody drug

This post was originally published on this site

While vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, AstraZeneca’s therapy Evusheld contains lab-made antibodies designed to linger in the body for months to contain the virus in case of an infection.

“Vaccines have proven to be the best defense available against COVID-19,” said Patrizia Cavazzoni, director of the Food and Drug Administration’s Center for Drug Evaluation and Research.

Pre-exposure prevention with Evusheld is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended, the FDA said.